Over the last few years there has been a shift in conducting clinical trials away from North America and Europe and towards emerging markets, particularly the BRIC countries. Rachel griffiths at Biotec Services International explains why drug companies have been nervous  to move new drug manufacturing to thesecountries, and how Brazil and India are expanding their development pharmaceutical manufacturing capability.
 
http://jforcs.com/jcs/wp-content/uploads/2013/08/4-Clinical-Supply-in-Emerging-Markets.pdf